OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Fiche publication
Date publication
juillet 2021
Journal
European urology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier
Tous les auteurs :
Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Morvan C, Campion L, Blanc-Lapierre A
Lien Pubmed
Résumé
Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in metastatic prostate cancer, and salvage pelvic radiotherapy may offer long ADT-free intervals for patients harboring regional nodal relapses.
Mots clés
Choline, Fluciclovine, Intensity-modulated radiotherapy, Lymphadenectomy, Oligometastases, Oligorecurrent, Pelvic radiotherapy, Positron-emission tomography prostate-specific membrane antigen, Prostate bed irradiation, Prostate cancer, Salvage, Stereotactic ablative radiotherapy, Stereotactic body radiotherapy, Stereotactic radiotherapy
Référence
Eur Urol. 2021 Jul 8;: